BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

BioReports - Visiongain

 
GSK's Cervarix a future blockbuster of 2007
The number of blockbusters continues to increase. The number is set to increase to 112 in 2007. Of the products set to receive FDA approval this year and generate blockbuster status on an annual basis, GSK's Cervarix, intended for the prevention of infection and lesions from the two cancer-causing types of HPVs holds great potential.
 
Cannabinoid Market Forecasts and Analysis to 2012
With 4 drugs now in the marketplace (a 100% rise from 2 years ago), the cannabinoid market continues to grow. Attitudes to the drugs are changing ensuring greater market penetration, and the first cannabinoid blockbuster is now a certainty.
 
AMD Market Outlook to 2012
AMD is the most common cause of vision loss in the developed world for those over 50 years of age. We estimate there are over 20 million cases in the US and Europe. Dry AMD accounts for 90% of cases and has no suitable cure. Wet AMD drug sales will soon see the first blockbuster. Novartis achieved first to market success with their Visudyne drug in 1999. However work from Pfizer selling Macugen and Lucentis from Genentech have seen it sales reduced. These drugs are refered to in the press as ‘miracle drugs’ – saving sight for millions. But issues over prescribing still remain.
 
The Global Rheumatoid Arthritis Market Forecasts to 2012
In a market believed to approach 5 million people in the leading pharma markets, the market for rheumatic anti-inflammatory drugs is both profitable and set to increase due to new launches. The annual revenue to Q3 2006, from the main prescription anti-inflammatory drugs worldwide, including non steroidal anti-inflammatories (NSAIDs), anti-rheumatic corticosteroid combinations and specific anti-rheumatics was in the order of $16bn worldwide. This market cannot be ignored. A life-long disease with no cure, the disease has been targeted greatly by pharma companies with the launch of novel targetted biologic therapies. However this has meant that the market for severe RA has become crowded - but is it saturated?
 
Tissue Engineering and Stem Cell Technology Report 2007
* * * Latest totally updated market focussed report, available now * * *

Over 160+ pages dedicated to tissue engineering and stem cell analysis.

The market potential of this technology is so huge that revenues may be in excess of $10 billion by 2013. This is a market that you should be part of - NOW!! With a complex regulatory structure still to overcome, yet continued high level investment, many of your competitors are aware of the the commercial opportunities within Tissue Engineering & Stem Cell Technology.
 
Novartis Market Outlook Forecasts and Analysis to 2012
With headquarters in Basel, Switzerland, Novartis is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, high revenue growth, acquisitions, breadth of portfolio, product launches and pipeline developments. In 2006 - ten years after its inception - Novartis generated total net sales of $37bn worldwide.
 
Biological Drug Delivery 2007-2012
The two major problems for biotech drugs are their mode of delivery and relative instability. The majority of delivery methods for biological drugs involve injection, which is not necessarily ideal for most indications. As the biotech sector starts to heat up, the industry has started to look for new ways of delivering these highly successful drugs.
 
The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012
'The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012' is a new report from visiongain providing analysis of the current and future market for IBD drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global IBD market. Autoimmune disease is a multimillion dollar market set to increase as world prevalence rates rise and the population lives longer. Inflammatory bowel disease (IBD) affect millions of people worldwide with 2.8 million currently diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD) in the US alone. The incidence of IBD is rising in developing countries around the world. Currently the global market is estimated at $16bn and this is set to continue to rise.
 
Theranostics Report 2007-2012
Key questions remain over theranostics. How can your company secure key successes and ideals in personalized medicine - aiming the right drug at the right person and at the right time. Plus with increased FDA regulation, how can we guarantee that that specific drug is safe for that individual. These issues are not going away, but one report can make it alot easier for you and your company.
 
Stem Cells - The hype and the hope - Business opportunities and forecasts
Stem cells are without doubt the most controversial area of science at the moment. The world markets have latched onto the potential offered by stem cells to modern medicine and, as a result, the research is in the public eye on an almost daily basis. Are you fully informed of the market potential of stem cell work? Do you know which companies and research organisations you must work with now? This report tells you.

So what is all the controversy about? And what products are we likely to see, in what areas and when, if stem cell work continues at pace?

 
World market for cancer vaccines 2007-2012
"Lung cancer vaccine to be tested" "New US bill requires cancer vaccine for girls" "Cancer vaccine too expensive".

These are just some of the news headlines that have seen the world cancer vaccine market turned on its head. The benefits are unquestionable, the costs of the drugs however may yet see take-up slow. How will this effect your company? This report will tell you.

There are two types of cancer vaccines:

> Prophylactic cancer vaccines, designed to prevent the development of cancer, they are given to healthy subjects to prevent infection with cancer-causing viruses

> Therapeutic cancer vaccines, designed to treat existing cancers, they are given to cancer patients to stimulate the immune system into recognising and destroying their existing cancer
 
Central and Eastern European CEE Developing Markets for Pharmaceuticals 2006-2011
The purpose of visiongain’s Developing Markets Series is to examine prospects for the growth of pharmaceutical revenues in the developing economies of Asia, Latin America and Eastern/Central Europe in three linked reports. Central and Eastern European (CEE) Developing Markets for Pharmaceuticals, 2006-2011 – Part 3 of Developing Markets - discusses prospects for the large developing market of Central and Eastern Europe. The other reports discuss Asia and Latin America respectively. Importantly, the growth of pharmaceutical markets in economically developing nations has the potential to offset serious problems currently being experienced by the global industry. The purpose of this visiongain report is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Central and Eastern Europe, at both regional and national level.
 
Therapeutic Monoclonal Antibodies, 2006-2011 Maximising the Growth Potential of a Stocked Pipeline
The monoclonal market is set to expand dramatically. Ten years ago there were only two monoclonal antibody drugs on the world market, now there are nineteen FDA approved therapies – including six blockbuster drugs. The market in 2005 was worth over $13bn, worldwide, representing an astounding growth of 37% - can you believe it? Well you should and to make sure you capture an increased share of this growth order this report NOW. Biotech pipelines are overflowing with over 160 monoclonal antibody based drugs; the market is thriving!

Will the current monoclonal blockbusters continue to grow? What are the hottest projects in the pipeline? What will restrain the market in the future? These are questions you need to know the answers to.

 
Latin American Developing Markets for Pharmaceuticals 2006-2011
The purpose of visiongain’s Developing Markets Series is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Asia, Latin America and Eastern/Central Europe. Latin American Developing Markets for Pharmaceuticals, 2006-2011 discusses prospects for the large developing market of Latin America. Importantly, the growth of pharmaceutical markets in Latin America has the potential to offset serious problems currently being experienced by your industry. The purpose of this visiongain report is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Latin America, at both regional and national level.
 
Achieving success in the Developing Asian Pharmaceutical Sector 2007-2011
Will the economic growth in new Asian markets allow you to offset global problems? With the Japan market slow and stagnant what other countries in the region offer you the greatest opportunities and how can you succeed in them. This report tells you.

Asian Developing Markets for Pharmaceuticals, 2006-2011 delivers to you unique prospects for the largest developing pharmaceutical market - Asia.

This report predicts that all the leading developing markets will exhibit strong growth from 2006-2011. Rapid economic growth and large, under-served populations will drive that expansion in pharmaceutical revenues. There will be significant growth in sales of both branded and generic drugs through increasing demand from both public and private healthcare sectors.
 
Bioinformatics Report - The forecasts and future of the market 2006-2011
"Outsourcing defines future of Euro Bioinformatics market"

"Jump on bioinformatics bandwagon"

These are just two newspaper headlines that appeared today. Managing your data is critical to your organisation. You already know that. But is your company doing it as effectively as it should? Find out by reading this brand new report.

This report delivers answers on how you can benefit from the commercial prospects of bioinformatics, now. The ultimate goal of bioinformatics is to uncover the wealth of biological information hidden in the mass of data, to obtain a clearer insight into the fundamental biology of organisms. Is your Bioinformatic strategy working to the maximum level. These recent developments have a profound relevance to pharmaceutical development.

 
Anti-addiction Therapies, 2006-2011 - The Pharmaceutical Industry’s Next Viagra?
More money is spent advertising alcohol than any other product. For some, it like gambling and cigerettes are pleasant distractions, yet for others they are the generators of unbearable cravings and the cause of considerable distress. For them their addition is a disease. According to a new report by visiongain - Anti-addiction Therapies, 2006-2011 - society is crying out for solutions. Which pharmaceutical companies are now aiming to be that cure? This report will tell you.
 
The World Allergy Market 2006-2011 - The Rx-OTC Rush
The number of people suffering from some sort of allergy is on the rise and the demand for reliable treatments for allergic rhinitis and other allergic conditions is on the rise worldwide. The market is a mature one with a number of high profile patent losses in the near future and a strong OTC segment. Will there be a replacement for Zyrtec or Allegra in the near Future? What role will the new improved vaccines play in the next five years? Read visiongain’s new report to find out.
The Global Biotech Report 2006 - The rise of the Biotech blockbusters
The Global Biotech Report 2006 - The rise of the Biotech blockbusters
In stark contrast to the rest of the pharmaceutical industry, the world market for biotech drugs is thriving. In 2005, biotech revenues reached $60bn and visiongain predicts that this will continue - YOU MUST BE PART OF THIS SUCCESS NOW. Having grown 16.5 per cent from 2004's revenues, double-digit growth of the market will continue to the end of the decade. You need to be aware of how you can succeed in this area. 1 report will tell you all you need to know.

- Over 250+ pages

- Over 150 tables and figures

- Global revenues & growth rates for the leading biotech drugs

- Company profiles of the leading biotech firms

- A comprehensive analysis of the global market, 2005-2011

- Revenue forecasts for the leading biotech drugs

- Revenues into therapeutic area

- Pipeline treatments

- A geographic breakdown of the market

- A Focus on biogenerics
 
Developing Markets for Pharmaceuticals, 2006-2011
The purpose of this visiongain report is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Asia, Latin America and Eastern/Central Europe at both regional and national level. The growth of pharmaceutical markets in the developing nations has the potential to offset serious problems currently experienced by the global industry. The principal challenge is slow growth in North America, Western Europe and Japan.
 
The World Asthma and COPD Treatment Market, 2006-2011 - A Changing Market with Increasing Potential
The asthma treatment market is a $15 billion market, driven by an increasing prevalence and yet without a treatment to cure this debilitating disease. All current drugs treat the symptoms but not the underlying cause. It is currently dominated by GSK with its $5.5 billion blockbuster, Advair/Seretide. However, this combination treatment is about to have its first real competition with Symbicort approved for the US market in July 2006. Combination drugs appear likely to dominate the mid-term forecast period as assessed by visiongain.
 
The World Contract Research and Manufacturing Market, 2006-2011 - Trends in Outsourcing
The Contract Pharma market in 2005 was worth an estimated $57bn. Attitudes within the pharmaceutical industry are slowly changing and the use of strategic outsourcing is becoming an accepted practice. Specialised technologies and a global presence are becoming more important for a greater number of pharmaceutical companies. Even big pharma is increasingly using outsourcing to spread the risk of development and lower fixed costs.
 
ePharma - The Online Pharmaceutical Industry, 2006-2011
The purpose of this visiongain report is to examine the commercial prospects of online technologies in the pharmaceutical sector. In particular, this report examines the fast-growing fields of pharmaceutical eMarketing, eDetailing, ePrescribing and online drug sales. Online technological solutions have great potential to benefit - even revolutionise – the marketing efforts of drug companies. Visiongain predicts that all aspects of pharmaceutical eMarketing will exhibit steady growth from 2006-2011. Key technological solutions - such as Internet-enabled DTC promotion, eDetailing and ePrescribing - will drive that expansion. Sales of prescription drugs via the Internet will also be significant.
 
Pharmacovigilance - Risk Management in Practice
At present ADRs are the sixth largest cause of death in the US. Drug safety is a huge issue facing the industry today and the risk is high with the possible loss of a key revenue producing drug coupled with potentially damaging litigation. The financial risk facing Merck on the withdrawal of Vioxx was considerably beyond the loss of its $2.5 bn yearly revenues.
 
Nanomedicine 2006-2011
The purpose of this visiongain report is to examine the commercial prospects of nanotechnology in medicine – the fast-developing and increasingly lucrative field of nanomedicine. Nanotechnology has great potential to benefit - even revolutionise - the pharmaceutical, medical devices, diagnostics and imaging sectors. Visiongain predicts that nanomedicine will exhibit strong growth in all sectors from 2006-2011, leading to multi-billion dollar revenues. Key technology platforms such as nanocrystals, nanotubes, dendrimers, fullerenes, quantum dots and molecular scaffolding will drive that market expansion.
 
Biogenerics 2006: Challenges ahead for an emerging market
The world biogenerics market is about to develop on a very large scale. The approval of generic growth hormones in the US and Europe has finally occurred and this has created a new source of revenue for generic companies. After years of indecision and false starts, it appears that generic biotech drugs are going to become available on the large, lucrative markets of the US and Europe. However, despite the introduction of Biosimilar guidelines by the EU and a heightening of the debate within the FDA, key questions for the pharmaceutical industry still remain concerning this new type of generic drug. The main issue is the degree to which the new biosimilar but not bioequivalent generic drugs will have to be tested prior to market launch. The delay in firm guidance and legislation is concerned almost entirely with this issue.
 
Indian Pharmaceutical Market, 2006-2011
The Indian pharmaceutical market is the 15th largest individual market by sales, but the 4th by volume of product. With domestic drug sales of almost $5 billion, Indian companies have also developed a considerable service industry for the global pharmaceutical market. However the Indian pharmaceutical market looks set for considerable change.
 
Product Lifecycle Management, 2006
The global pharmaceutical market with sales of approximately $550 billion is about to enter a pivotal period in its history. The industry has been used to double digit growth rates but growth has now dropped to below 10% for the first time. In addition to this whole swathes of lucrative high revenue earning drugs are going to lose patent. Ordinarily, the industry would have been able to cope with this after all patent loss is a normal part of the industrial process. But this time the industry faces serious problems, pipelines are notoriously thin. The industry is going to have huge difficulties in replacing those drugs going off patent and the high levels of revenue that they earn. The industry is going to have incorporate the new culture of Product Lifecycle Management (PLM) if it is to salvage some of those lost revenues.
 
The World Generics Market 2006-2011
In sharp contrast to the branded pharmaceutical market, which has stalled in recent year, the generics market is enjoying a period of unprecedented success. In 2005 the world generics market was worth $45bn, a growth of 14% on the previous year. Visiongain expects this level of growth to continue over the forecast period of this report.
 
The World Diabetes Market, 2005-2011
Diabetes effects approximately 170 million people worldwide and is increasing, with the WHO predicting 300 million diabetics by 2025. The US alone has 20.8 million people suffering with diabetes. This equates to approximately 6% of the population. It was the 6th most common cause of death as recorded on US death certificates.
 
The Clinical Trials Market 2006
 
The World Gastrointestinal Disorders Market 2006-2011
The purpose of this visiongain report is to examine the prospects of the world gastrointestinal market. The gastrointestinal (GI) disorders market is one of the largest and most important in the pharmaceutical industry, generating revenues of over $16 billion in 2004.
 
Japanese Pharmaceutical Market, 2006-2011
The Japanese pharmaceutical market is the second largest individual market and with sales of $60 billion constitutes approximately 11% of the world market. However, it is a market that frustrates the major pharmaceutical companies as it is growing at a significantly lower rate of growth than the average of the world pharmaceutical markets.
 
The World Market for Antidepressants, 2006
In 2004 total world revenues for branded antidepressant drugs was worth over $13bn, but with only ten drugs on the market. However, nine out of these ten drugs faces a loss of patent in the period 2006-2010.

Dr Tom Newton, pharmaceutical analyst with visiongain and author of The World Market for Antidepressants, 2006, predicts that the world market will crash producing revenues in 2010 of only $7bn. This is a loss of almost 50% of total revenues.

 
The World’s Top Ten Generic Companies
Generic companies and the drugs they produce are now an important part of the major pharmaceutical markets. The growth rate in the industry is increasing, nine of the top ten fastest growing pharmaceutical companies are generic and the demand for cheaper drugs is increasing.
 
The World Hypertension Market 2005-2010
The world hypertension market generated over $25 billion in 2004, with steady growth from the previous year. In this report, visiongain forecasts that revenues in the world hypertension market will grow to nearly $30 billion per year by 2010.
 
Pfizer - Current Difficulties and Future Challenges, 2005-2010
Pfizer has just issued a warning on how deep the pharmaceutical industry's problems have gone. The company has cut its profit expectations for this year.
 
The World Sleep Disorders Market, 2005-2010
The sleep disorder treatment market had sales of $2.03bn in 2004. It is dominated by one product, Ambien indicated for the short-term treatment of insomnia and providing Sanofi-Aventis with an 87% market share.
 
The World Schizophrenia Market 2005-2010
The schizophrenia world market generated total revenues of nearly $12 billion in 2004. The market is growing now. Are you capitalising on this market?
 
Pricing and Reimbursement 2005 - 2006, Evaluating Ket Strategic Issues
One of the two major issues for a drug company, besides gaining market authorisation, is persuading the country in question to reimburse them, that is pay for the drug that the company is attempting to market.
 
The World Biotech Market 2005
The biopharmaceutical market has undergone rapid expansion since its emergence thirty years ago. No longer is the market confined to growth hormones, insulin and red blood cell stimulating agents.
 
The World Pharmaceutical Wholesale and Distribution Industry 2005
The Pharmaceutical Wholesale and Distribution Industry has survived on continual low profits while the pharmaceutical companies of whom its serves continues to thrive. The major problem facing the industry today is how to increase its profitability.
 
World Neurodegeneratives Disease Markets, 2005-2009
Is the neurodegeneratives disease market growing? Are current drug therapies valuable? What are the current unmet needs in this market? What is the future of this market?
 
Urinary Track Agents Annual Report 2005
Urinary tract agents (UTAs) are simply drugs used to treat disorders of the urinary tract. They do not treat infections of the urinary tract (UTIs) as some antibiotics do, but these drugs may provide relief from the symptoms of a UTI.
 
The Global Endocrine Pharmaceutical Market 2005
Today, the global endocrine pharmaceutical market is a highly lucrative multi-billion dollar business, but, can you confidently answer the following?
 
The Global Veterinary Pharmaceutical Market
The animal health businesses of the major pharma companies have two parts: one for food producing animals and one for companion animals such as dogs and cats.
 
Anticonvulsants 2005
Anticonvulsant therapies encompass all drugs used primarily to prevent seizures or control their incidence or severity. These drugs are however versatile and can be used for a variety of other disorders, namely bipolar disorder, neuropathic pain and migraine prophylaxis.
 
Therapeutic Proteins
Proteins that are engineered in the laboratory for pharmaceutical use are known as therapeutic proteins. The majority of biopharmaceuticals marketed to date are recombinant therapeutic protein drugs.
 
Cannabinoids: A potential blockbuster?
Today's cannabinoid market is undergoing rapid expansion. Currently just two products are available on this controversial market: Marinol from Unimed Pharmaceuticals and Nabilone marketed by Cambridge Laboratories. Both indicated for the control of chemotherapy- induced nausea and vomiting, Marinol has additional approval as an appetite stimulant to treat anorexia assocaited with HIV/AIDS.
 
Pharmacoeconomics
Pharmacoeconomics is the branch of economics that applies cost-benefit, cost-effectiveness, cost-minimisation, and cost-utility analyses to compare the economics of different pharmaceutical products or to compare drug therapy to other treatments.

BioPortfolio's BioReports catalogue is one of the most comprehensive sources of specialized life science management reports on the internet. You can search our database by using the links below:

If you represent a publisher who wishes to market via BioPortfolio's BioReports service please contact Peter Barfoot.

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.